Literature DB >> 22161814

Suppression assays with human T regulatory cells: a technical guide.

Alicia N McMurchy1, Megan K Levings.   

Abstract

The suppression of inappropriate immune responses by Treg cells is one of the major ways that the body maintains immune tolerance and homeostasis. Since defects in the suppressive capacity of Treg cells underlie many different immune-mediated diseases, there is great interest in developing ways to track the number and function of Treg cells as biomarkers of tolerance and in devising ways to enhance their function therapeutically. However, the methods of studying human Treg cells are fraught with technical challenges that can often lead to misinterpretation. The most common way to determine the suppressive capacity of human Treg cells is to measure their ability to suppress the proliferation of responding CD4(+) T cells. Here, we discuss the technical considerations that must be taken into account when performing suppression of T-cell proliferation assays with human Treg cells. We also consider how T cells may falsely appear suppressive because of dying cells in the system, improper resting of T-cell lines prior to the assay, or insufficient proliferation of the responding T cells. We propose that, in the future, classification of a population of cells as "regulatory" should rely on more than a simple test for blockade of CD4(+) T-cell proliferation.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22161814     DOI: 10.1002/eji.201141651

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  54 in total

1.  Semaphorin 4A Stabilizes Human Regulatory T Cell Phenotype via Plexin B1.

Authors:  Svetlana P Chapoval; Molly Hritzo; Xiulan Qi; Luca Tamagnone; Amit Golding; Achsah D Keegan
Journal:  Immunohorizons       Date:  2019-02

2.  Inhibition of microRNA-155 ameliorates experimental autoimmune myocarditis by modulating Th17/Treg immune response.

Authors:  Lianhua Yan; Fen Hu; Xiaofei Yan; Yuzhen Wei; Wenhan Ma; Ya Wang; Shuai Lu; Zhaohui Wang
Journal:  J Mol Med (Berl)       Date:  2016-04-06       Impact factor: 4.599

3.  Severe Congenital Neutropenia associated with SRP54 mutation in 22q11.2 Deletion Syndrome: Hematopoietic Stem Cell Transplantation Results in Correction of Neutropenia with Adequate Immune Reconstitution.

Authors:  Marcus A Carden; James A Connelly; Elizabeth P Weinzierl; Lisa J Kobrynski; Shanmuganathan Chandrakasan
Journal:  J Clin Immunol       Date:  2018-06-29       Impact factor: 8.317

4.  TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions.

Authors:  Pradeep B J Reddy; Taylor H Schreiber; Naveen K Rajasagi; Amol Suryawanshi; Sachin Mulik; Tamara Veiga-Parga; Toshiro Niki; Mitsuomi Hirashima; Eckhard R Podack; Barry T Rouse
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

5.  In Vitro Differentiation of Human CD4+FOXP3+ Induced Regulatory T Cells (iTregs) from Naïve CD4+ T Cells Using a TGF-β-containing Protocol.

Authors:  Angelika Schmidt; Szabolcs Éliás; Rubin N Joshi; Jesper Tegnér
Journal:  J Vis Exp       Date:  2016-12-30       Impact factor: 1.355

6.  A novel method for assaying human regulatory T cell direct suppression of B cell effector function.

Authors:  Elizabeth Weingartner; Jean-Paul Courneya; Achsah Keegan; Amit Golding
Journal:  J Immunol Methods       Date:  2016-11-13       Impact factor: 2.303

7.  LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes.

Authors:  Qianxia Zhang; Maria Chikina; Andrea L Szymczak-Workman; William Horne; Jay K Kolls; Kate M Vignali; Daniel Normolle; Maria Bettini; Creg J Workman; Dario A A Vignali
Journal:  Sci Immunol       Date:  2017-03-31

8.  Mesenchymal stem cells alleviate atherosclerosis by elevating number and function of CD4(+)CD25 (+)FOXP3 (+) regulatory T-cells and inhibiting macrophage foam cell formation.

Authors:  Zhi Xiao Wang; Chong Quan Wang; Xiao Yan Li; Gao Ke Feng; Hong Ling Zhu; Yan Ding; Xue Jun Jiang
Journal:  Mol Cell Biochem       Date:  2014-11-12       Impact factor: 3.396

Review 9.  Immune monitoring as prerequisite for transplantation tolerance trials.

Authors:  K Behnam Sani; B Sawitzki
Journal:  Clin Exp Immunol       Date:  2017-06-23       Impact factor: 4.330

10.  Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells.

Authors:  A S W Tjon; T Tha-In; H J Metselaar; R van Gent; L J W van der Laan; Z M A Groothuismink; P A W te Boekhorst; P M van Hagen; J Kwekkeboom
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.